



Introduction: The determination of lipid biomarkers by capillary sampling may be useful in the screening, diagnosis and/or personal management 
of hyperlipidemia and cardiovascular risk. It remains unclear whether the use of the Accutrend® Plus system is appropriate. This study aimed to assess 
its reproducibility, accuracy and concordance for blood lipid profi ling in adults.
Materials and methods: Fasting capillary total cholesterol (TC) and triglyceride (TG) concentration on Accutrend® Plus were compared with their 
venous analogues obtained by a laboratory reference method in sixty-one adults (27 men and 34 women, aged 33.0 years). Supplementary capillary 
sampling was performed at two consecutive days taking into account macro-nutrient intake.
Results: The day-to-day reproducibility of the Accutrend® Plus system proved to be high for TC (ICC = 0.85, P < 0.001), but moderate for TG (ICC = 
0.68, P < 0.001). Strong correlations (r ≥ 0.80, P < 0.001) with the reference method were found for TC and TG. Mean diff erence (limits of agree-
ment) were: 0.26 mmol/L (-0.95, 1.47) for TC, and -0.16 mmol/L (-1.29, 0.98) for TG. The concordance for subject classifi cation according to the Na-
tional Cholesterol Education Program (NCEP) guidelines was signifi cant (P < 0.001), with substantial agreement for TC (κw = 0.67), and moderate 
agreement for TG (κw = 0.50).
Conclusions: Day-to-day reproducibility of the Accutrend® Plus device for TC and TG is not optimal and lacks accuracy when compared to the re-
ference laboratory method. The concordance between both methods for classifying subjects according to the NCEP is inadequate. Accutrend® Plus 
device should not be interchangeably used as a substitution for the standard laboratory methods in the diagnosis of hyperlipidemia.
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Introduction
Elevated concentrations of lipids in the blood have 
been associated with an increased risk of cardio-
vascular morbidity and mortality (1). Monitoring 
cardiovascular disease risk and reducing the onset 
of cardiovascular events by therapeutic lifestyle 
changes and drug therapy has received increasing 
international attention since 1980 (2,3). The detec-
tion, evaluation and treatment of hyperlipidemia 
are based on circulating blood lipid concentrations 
among which total cholesterol (TC) and triglycer-
ides (TG). The classifi cation of individuals based on 
lipid profi le represents a general guidance for clin-
ical decision making.
In this context, portable devices such as the Accu-
trend system (Roche Diagnostics GmbH, Man-
nheim, Germany) off er a number of advantages 
over conventional laboratory machinery. The ma-
jor benefi ts include fast, minimally invasive and 
easy blood collection, and immediate ambulatory 
determination of blood lipid profi le. In the past, 
validation of the capillary Accutrend system for 
the measurement of circulating lipids has led to 
confl icting results (4-11). In a number of studies, 
the Accutrend was found to be suffi  ciently accu-
rate for clinical use; conversely, others concluded 
that the precision and the control range of the 
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measuring device (i.e. range of 3.88-7.76 mmol/L 
for TC and 0.80-6.86 mmol/L for TG) are insuffi  -
cient for patient evaluation (4-11). The control 
range is the measurement range in which the Ac-
cutrend produces “real” values of the concentra-
tion of blood markers. Within this range linearity 
of the method is insured by the manufacturer. Be-
low or above this measurement range the Accu-
trend produces no exact values, but gives an indi-
cation of the value with “low” or “high”. There is 
evidence indicating that the newly developed Ac-
cutrend® Plus device (Roche Diagnostics GmbH, 
Mannheim, Germany) has been improved for in 
vivo diagnostic use (9). However, validation of this 
upgraded optical refl ectance system is scarcely re-
ported in the scientifi c literature. Since it remains 
unclear under which circumstances the use of this 
particular system is appropriate, the aims of this 
study were: 1) to determine the day-to-day repro-
ducibility of the Accutrend® Plus device; 2) to as-
sess the accuracy of the Accutrend® Plus system by 
comparing its results to those obtained by a refer-
ence laboratory method for monitoring lipid pro-
fi le in adults; and 3) to assess the concordance be-
tween both methods for classifying subjects ac-




Twenty-seven male volunteers with a median age 
of 32.0 years (ranging from 19 to 70 years) and thir-
ty-four female volunteers with a median age of 
33.5 years (ranging from 20 to 69 years) were re-
cruited by advertising in the Greater Brussels area, 
Belgium. All participants were apparently healthy 
and without cardiovascular history. The study pro-
cedures were in accordance to the World Medical 
Association’s Declaration of Helsinki (12). The study 
protocol was approved by the local ethical com-
mittee and all participants provided written in-
formed consent.
Methods
All venous and capillary blood lipid concentrations 
were determined in the morning after an over-
night fasting period of at least eight hours. In each 
subject venous and capillary blood samples were 
collected at the same time. Supplementary capil-
lary sampling was performed at two consecutive 
days following the fi rst collection. Capillary TC and 
TG concentrations were determined with the Ac-
cutrend® Plus using two drops of blood (15-40 μL) 
collected from diff erent fi ngers, by using a lancing 
device (Accu-chek® Softclix® Pro, Roche Diagnos-
tics GmbH, Mannheim, Germany). The Accutrend® 
Plus test is a capillary serum test. It is based on the 
retention of blood cells by fi ltration via a glass fi -
bre fl eece when a drop of blood is applied to the 
test strip. The enzymatic reaction that takes place 
in the underlying zone of the strip requires an ad-
equate oxygen supply and results in the formation 
of a colored oxidation product. The refl ectance of 
the strip (measured at 660 nm) is converted to con-
centration through a simple algorithm. The intra-
assay precision of Accutrend® Plus, as determined 
by the manufacturer, was 3.7% and 3.4% for TC 
and TG respectively. The inter-assay precision for 
Accutrend® Plus determined with control solution 
by the manufacturer was lower than 5.0% for TC 
and 2.4% for TG.
Venous blood was collected in Sarstedt S-Mon-
ovette® 4.9 mL lithium heparin gel tubes (Sarstedt 
AG & Co., Nümbrecht, Germany), by using a Ter-
muro® Surfl o® winged infusion set (Termuro Eu-
rope N.V., Leuven, Belgium). Sera obtained from 
the venous blood samples were analyzed (blinded 
for capillary-based values) on a Vitros® 5.1 FS chem-
istry system (Ortho-Clinical Diagnostics, Johnson 
& Johnson, Beerse, Belgium), a Cholesterol Refe-
rence Method Laboratory Network certifi ed sys-
tem, using the manufacturer’s reagents and cali-
brators (13,14). For TC and TG, 5.5 μL of sample was 
measured by multilayer fi lm dry-slide chemistry 
with colorimetric detection. The intra-assay preci-
sion of Vitros® 5.1 FS, as determined by the manu-
facturer, was 0.7% for TC and TG. The inter-assay 
precision was 1.5% and 1.4% for TC and TG respec-
tively. Venous blood sample analysis was per-
formed at the hematology laboratory of the Uni-
versitair Ziekenhuis Brussel (Brussels, Belgium), an 
ISO 15189 accredited laboratory for clinical biolo-
gy. TC concentration was classifi ed as: ‘normal’ 
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when TC < 5.18 mmol/L; ‘borderline’ when 5.18 
mmol/L ≤ TC < 6.22 mmol/L and ‘high’ when TC ≥ 
6.22 mmol/L. TG concentration was considered as: 
‘normal’ when TG < 1.69 mmol/L, ‘borderline high’ 
when 1.69 mmol/L ≤ TG < 2.26 mmol/L; ‘high’ 
when 2.26 mmol/L ≤ TG < 5.64 mmol/L and ‘very 
high’ when TG ≥ 5.64 mmol/L (3).
In order to assess diff erences in daily caloric and nu-
tritional intake all participants completed a self-ad-
ministered questionnaire containing a personal 
three-day food diary based on the National Health 
Survey (a validated instrument used to estimate 
health-related issues in the Belgian population every 
5 years (15)), that started at the day of venous blood 
collection. Daily nutritional intake was calculated us-
ing an online diet planner (Nubel vzw, Brussels, Bel-
gium) supported by the Federal Public Service for 
Health, Food Chain Safety and Environment (16).
Statistical analysis
The control range of the Accutrend® Plus has not 
changed compared to the older Accutrend devices 
(Accutrend GC, Accutrend GCT). Values outside the 
control range set up by the manufacturer (3.88-
7.76 mmol/L for TC, and 0.80-6.86 mmol/L for TG) 
were excluded for statistical analysis. Normality of 
all data was verifi ed using Kolmogorov-Smirnov 
goodness of fi t tests.
The day-to-day reproducibility of the Accutrend® 
Plus system was assessed by computing diff erences 
between two consecutive assessments (24 h and 
48 h following baseline) using paired samples t-
tests and by calculating intra-class correlation co-
effi  cients (ICC, model 2.1) (17). The standard error 
of measurement (SEM = σ x ICC−1 , with σ = 
standard deviation of the test and the retest capil-
lary values) and the smallest detectable change 
(SDC = 1.96 x 2  x SEM) were calculated (18). To 
verify that test-retest results obtained by the Accu-
trend® Plus were unaff ected by the diet of the vol-
unteers, macro-nutrient intake obtained by 24h 
food diaries preceding both test and retest were 
compared by paired samples t-tests or Wilcoxon 
signed rank tests.
The accuracy of the Accutrend® Plus for measuring 
TC and TG was determined by comparing the re-
sults with those of the simultaneously sampled ve-
nous blood results using paired samples t-tests and 
Pearson’s correlation coeffi  cients. The agreement 
between capillary Accutrend and reference method 
was assessed using Passing and Bablok regression 
and Bland and Altman analysis (19,20). A diff erence 
between methods not exceeding 8.9% for TC and 
15% for TG, as stated by NCEP recommendations, 
was regarded as clinically acceptable (3).
Additionally the classifi cation of the participants 
according to the NCEP for TC and TG was com-
pared between both methods using Fisher’s exact 
tests and weighted kappa statistics (κw). For the in-
terpretation of the kappa values the following cri-
teria were applied: κ > 0.80 “excellent agreement”, 
0.80 ≤ κ < 0.60 “substantial agreement”; 0.40 ≤ κ ≤ 
0.60 “moderate agreement”, and κ < 0.40 “poor to 
fair agreement” (21).
Data were analyzed by using IBM® SPSS® Statistics 
version 20 (2011, SPSS Inc., New York, USA) or Med-
calc version 12 (Medcalc Software, Mariakerke, Bel-
gium). Group data are expressed as mean ± SD and 
statistical signifi cance was set at P< 0.05.
Results
Out of the 61 measurements obtained by the Ac-
cutrend® Plus, one value for TC level (above the 
higher limit) and 13 values for TG level (11 below 
the lower limit and 2 above the higher limit) fell 
outside the measurement range determined by 
the manufacturer.
Reproducibility of the Accutrend® Plus
No signifi cant diff erences in calorie or nutrient in-
take were found between the fi rst and second day 
of observation (Table 1).
The day-to-day reproducibility of the Accutrend® 
Plus proved to be high for TC concentration (ICC = 
0.85, P < 0.001), but moderate for TG concentration 
(ICC = 0.68, P < 0.001). No signifi cant diff erences in 
mean lipid concentration between both assess-
ments were found (Table 2). At a 24 h interval, 
smallest detectable changes of 0.75 mmol/L for TC 
concentration and 0.88 mmol/L for TG concentra-
tion were found.
Accuracy of the Accutrend® Plus
Table 3 summarizes the results for TC and TG con-
centration obtained by Accutend® Plus compared 
with the criterion method.
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Parameter Day 1 Day 2 P
Total energy (kcal) 2153.5 ± 827.9 2241.1 ± 783.5 0.571a
Total energy (kJ) 9008.0 ± 3463.8 9384.3 ± 3272.4 0.560a
Protein (g) 84.6 ± 52.8 80.5 ± 42.6 0.531a
Fat (g) 71.8 ± 32.9 77.5 ± 34.8 0.525a
 Saturated fatty acid (g) 24.7 ± 15.7 26.2 ± 13.1 0.674a
 Monounsaturated fatty acid (g) 17.3 ± 9.0 17.5 ± 13.5 0.956a
 Polyunsaturated fatty acid (g) 8.2 ± 4.5 9.7 ± 8.2 0.363a
 Omega-3 fatty acid (g) 0.2 (0.2-0.7) 0.4 (0.2-0.6) 0.147b
 Omega-6 fatty acid (g) 3.2 ± 1.8 4.0 ± 3.3 0.290a
 Linoleic acid (g) 3.7 ± 2.2 4.3 ± 3.7 0.470a
 Trans fatty acid (g) 0.4 ± 0.4 0.5 ± 0.6 0.441a
 Cholesterol (mg) 187.7 ± 179.7 162.6 ± 133.5 0.372a
Carbohydrate (g) 228.0 ± 85.2 244.5 ± 87.9 0.317a
 Sugar (g) 89.2 ± 45.3 98.8 ± 55.0 0.441a
 Amylum (g) 103.3 ± 55.0 103.4 ± 58.8 0.991a
Fiber (g) 14.9 ± 6.6 15.8 ± 8.6 0.475a
Water (g) 1160.2 ± 698.5 1131.0 ± 738.0 0.812a
Alcohol (g) 0.0 (0.0-46.4) 19.8 (0.0-49.5) 0.852b
Data are presented as mean ± standard deviation or as median (interquartile range). apaired t-test, bWilcoxon signed rank test.
TABLE 1. Daily caloric and nutrient intake of the volunteers before capillary Accutrend® Plus test and retest assessments.
N 24 h 48 h Mean diff erence(95% CI)
ICC
(95% CI) SEM SDC P
Total cholesterol 39 4.83 ± 0.70 4.86 ± 0.70 -0.03 (-0.15-0.10) 0.85 (0.73-0.92) 0.27 0.75 0.670
Triglycerides 29 1.46 ± 0.56 1.46 ± 0.57 0.002 (-0.17-0.18) 0.68 (0.42-0.83) 0.32 0.88 0.975
Data are presented as mean ± standard deviation.
ICC - Intra Class Correlation coeffi  cient (model 2.1); CI - confi dence interval; SEM - standard error of measurement; SDC - smallest detectable 
change.
TABLE 2. Measurement reproducibility of capillary lipid concentrations (mmol/L) at 24h interval obtained by Accutrend® Plus.
N Vitros1 Accutrend Plus2 r P
Passing-Bablok regression
P
Intercept (95% CI) Slope (95% CI)
Total cholesterol 60 5.18 ± 1.20 4.92 ± 0.78 0.89 <0.001 -1.66 (-2.73-0.71) 1.38 (1.19-1.60) 0.002
Triglycerides 48 1.47 ± 0.89 1.63 ± 0.91 0.79 <0.001 -0.24 (-0.62-0.01) 1.07 (0.85-1.33) 0.067
Data are presented as mean ± standard deviation.
1 venous - obtained by venipuncture in the anterior cubital region; 2 capillary - obtained by pin-prick in the fi ngertip;
r - Pearson correlation coeffi  cient; CI - confi dence interval.
TABLE 3. Comparison between venous and capillary lipid concentration (mmol/L).
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Despite a good correlation for the measurement 
of TC (r = 0.89, P < 0.001) between methods, the 
Accutrend® Plus signifi cantly (P = 0.002) underesti-
mated TC concentration. Passing-Bablok regres-
sion indicated a systematic (constant and propor-
tional) diff erence between methods (Figure 1A). 
For TC, the estimated bias was 0.26 mmol/L (95% 
CI 0.10 to 0.42) and 95% limits of agreement were 
(-0.95, 1.47 mmol/L) (Figure 1B).
For the determination of TG a fair correlation (r = 
0.79, P < 0.001) between methods was found with-
out signifi cant diff erence (P = 0.067). Passing and 
Bablok regression analysis indicated good agree-
ment between methods, without systematic and 
proportional diff erence between methods (Figure 
2A). Although the small mean diff erence of -0.16 
mmol/L (95% CI -0.32 to 0.01) was not signifi cant, 
95% limits of agreement of (-1.29, 0.98 mmol/L) 
were wide, refl ecting substantial variability of indi-
vidual diff erences between methods (Figure 2B).
Concordance of the Accutrend® Plus
The classifi cation of individuals according to the 
NCEP based on lipid profi le obtained by both 
methods is shown in Table 4.
For TC level, the percentage of subjects within 
‘risk’-groups did not diff er between methods (P < 
0.001, Fisher’s exact test). A substantial agreement 
was found (κw = 0.67). Eighty-two percent of the 
volunteers were classifi ed in the same group by 
VITROS ® 5.1 FS




Normal 33 6 1 -
Borderline high 0 13 4 -
High 0 0 4 -
Very high - - - -
TG*
Normal 39 1 1 0
Borderline high 5 3 1 0
High 2 2 5 1
Very high 0 0 1 0
NCEP - National Cholesterol Education Program; TC - total cholesterol: normal (< 5.18 mmol/L), borderline high (5.18-6.21 mmol/L), high 
(≥ 6.22 mmol/L); TG - triglycerides: normal (< 1.69 mmol/L), borderline high (1.69-2.25 mmol/L), high (2.26- 5.63 mmol/L), very high (≥ 5.64 
mmol/L); *P < 0.001, Fisher’s exact test.
TABLE 4. Concordance between Accutrend® Plus and Vitros® 5.1 FS for classifying 61 subjects following total cholesterol and triglycer-
ide levels according to the NCEP guidelines.
the Accutrend® Plus and the reference method, 
while 18% was classifi ed in a ‘lower’ risk group by 
Accutrend® Plus.
For TG level, the percentage of subjects within 
‘risk’-groups did not diff er between methods (P < 
0.001, Fisher’s exact test). A moderate agreement 
was found (κw = 0.50). Seventy-seven percent of 
the volunteers were equally classifi ed using values 
obtained by both methods. Based on the Accu-
trend® Plus, 7% was classifi ed in a group with ‘less’ 
risk, while the remaining 16% was classifi ed in a 
group at ‘higher’ risk compared to the reference 
method.
Discussion
Today the Accutrend® Plus system is used by phy-
sicians, nutritionists, patients as well as researchers 
in screening and diagnosis of hyperlipidemia; or to 
monitor the eff ects of diet or drug therapy on lipid 
profi le (22,23). Subjects that are at increased CVD 
risk may benefi t from a user-friendly system to 
monitor the eff ects of treatment thus stimulating 
personal health management. In this context, it 
has recently been shown that self-monitoring of 
blood lipids in patients with severe hypertriglycer-
idemia favors treatment compliance (24). Most of 
the previous validation studies involving the Accu-
trend system have been carried out in laboratory 
circumstances. However this portable device has 
Biochemia Medica 2012;22(1):100–8
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FIGURE 1A. Passing-Bablok regression plot for total cholesterol 
determined on Vitros® 5.1 FS and Accutrend® Plus, N = 60; con-
centration range 3.88–7.77 mmol/L; Pearson correlation coeffi  -
cient r = 0.89, P < 0.001.
FIGURE 1B. Bland and Altman plot for the diff erence between 
Vitros® 5.1 FS and Accutrend® Plus total cholesterol concentra-
tion (mmol/L).
FIGURE 2A. Passing-Bablok regression plot for triglycerides de-
termined on Vitros® 5.1 FS and Accutrend® Plus, N = 48; concen-
tration range 0.79–6.77 mmol/L; Pearson correlation coeffi  cient 
r = 0.79, P < 0.001.
FIGURE 2B. Bland and Altman plot for the diff erence between 
Vitros® 5.1 FS and Accutrend® Plus triglyceride concentration 
(mmol/L).
been designed for home or ambulatory use. This 
study is the fi rst to validate the Accutrend® Plus 
outside a laboratory setting.
In the present study, the day-to-day reproducibili-
ty of the Accutrend® Plus proved to be high for the 
measurement of TC (ICC = 0.85) and moderate for 
TG (ICC = 0.68). Since the measurement of lipid 
concentration was carried out after a fasting peri-
od of at least 8 hours without diff erences in nutri-
ent intake 24h before sampling, one might expect 
similar values at a 24 hour interval. It is generally 
accepted that an intra-individual biological vari-
ability of respectively 3.9% and 14.0% for TC and 
TG concentration is to be considered as normal 
(25). Taking this natural variability into account, the 
day-to-day reproducibility for lipid concentration 
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by Accutrend® Plus remained within the limits of 
biological variability. However, day-to-day diff er-
ences less than 0.75 mmol/L (29 mg/dL) for TC and 
0.88 mmol/L (78 mg/dL) for TG are to be consid-
ered non-signifi cant. It is therefore suggested that 
the values mentioned above represent the small-
est detectable changes during follow-up using the 
Accutrend® Plus system.
The results of our study show that capillary blood 
lipids are well correlated (r-values ≥ 0.80, P < 0.001) 
with their venous analogues. Bland-Altman analy-
sis showed that, on average, Accutrend® Plus tend-
ed to underestimate venous TC by 0.26 mmol/L. 
This is in agreement with previous fi ndings (7,26). 
The agreement between methods fell outside clin-
ically acceptable limits of ≤ 8.9%, as stated by NCEP 
recommendations for cholesterol measurement. 
Further research is required to determine the ex-
act reasons for the consistence diff erences in TC 
concentration. In the present study, Accutrend® 
Plus overestimated venous TG concentration by 
0.16 mmol/L. This overestimation in capillary blood 
has been reported previously (5,10,26,27). Since 
lipids are being consumed by the cells, fi ngerstick 
capillary TG concentration should be higher than 
venous TG concentration. Therefore, overestima-
tion of TG concentration by the Accutrend® Plus in 
the present study might be explained by diff erent 
hemodynamic conditions in the capillary bed. 
However, the level of agreement between capil-
lary and venous TG resulted in clinically important 
discrepancies of ± 75% (± 1.14 mmol/L), and ap-
peared to worsen with increasing values. This vari-
ability should not be ignored when developing a 
protocol for triglyceride screening.
Based on the ‘cardiovascular risk’ classifi cation of 
subjects according to lipid concentration, an ac-
ceptable concordance between Accutrend® Plus 
and the laboratory reference was found. However, 
the former tended to underestimate CVD risk 
based on TC concentration, while mainly overesti-
mating CVD risk based on TG level.
All results considered, the present study suggests 
that day-to-day reproducibility of the Accutrend® 
Plus device for TC and TG is not optimal and lacks 
accuracy when compared to the reference labora-
tory method. The concordance between both 
methods for classifying subjects according to the 
NCEP is not adequate. Accutrend® Plus device 
should not be interchangeably used as a substitu-
tion for the standard laboratory methods in the di-
agnosis of hyperlipidemia.
This study did not evaluate potential infl uence of 
bilirubin, hemoglobin, free glycerol or ascorbic 
acid on cholesterol and/or triglyceride concentra-
tion using an enzymatic oxidase/peroxidase assay 
as is the case with the Accutrend® Plus. Therefore 
the interference of the above mentioned biomol-
ecules with Accutrend® Plus accuracy cannot be 
excluded (28,29). However the volunteers in the 
present study did not follow any specifi c diet, nor 
used vitamin supplements or medications, there-
by reducing the risk of erroneous measurements.
Conclusion
Accutrend® Plus TC and TG concentration corre-
lates satisfactorily with its laboratory analogue. 
However, higher precision for the determination 
of lipid profi le is warranted, especially for the mea-
surement of TG concentration. Although the Accu-
trend® Plus system may provide useful information 
for the referral of persons at cardiovascular risk, 
this device should not be used as a substitution for 
the laboratory methods in the diagnosis of hyper-
lipidemia. Given its day-to-day reproducibility, the 
Accutrend® Plus might be used as a system for self-
monitoring. Under constant diet circumstances, 
fl uctuations of 0.75 mmol/L (29 mg/dL) for TC and 
0.88 mmol/L (78 mg/dL) for TG are to be consid-
ered as non-signifi cant.
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Scafoglieri A. et al. Blood lipids on Accutrend® Plus
Ponovljivost, točnost i podudarnost sustava Accutrend ® Plus pri određivanju 
koncentracije cirkulirajućih lipida kod odraslih
Sažetak
Uvod: Određivanje lipida uzorkovanjem kapilarne krvi može se primijeniti pri probiru, dijagnozi i/ili osobnom praćenju hiperlipidemije i kardi-
ovaskularnog rizika. Pitanje je li sustav Accutrend® Plus primjeren za taj zadatak ostaje još nerazjašnjeno. Ovim istraživanjem želimo procijeniti 
ponovljivost, točnost i podudarnost sustava pri određivanju lipidnog statusa krvi kod odraslih osoba.
Materijali i metode: Rezultati određivanja koncentracije ukupnog kolesterola (engl. total cholesterol, TC) i triglicerida (TG) natašte iz kapilarne 
krvi na sustavu Accutrend® Plus uspoređeni su s rezultatima analognih pretraga iz venske krvi dobivenih referentnim laboratorijskim metodama 
kod 61 odrasle osobe (27 muškaraca i 34 žena, median dobi 33,0 godine). Dodatno uzorkovanje kapilarne krvi provedeno je dva dana za redom 
vodeći računa o unosu makronutrijenata.
Rezultat: Ponovljivost iz dana u dan na sustavu Accutrend® Plus bila je visoka za TC (ICC = 0,85, P < 0,001), no umjerena za TG (ICC = 0,68, P < 
0,001). Za oba parametra TC i TG dobivene su jake korelacije (r ≥ 0,80, P < 0,001) s referentnom metodom. Granice podudaranja srednjih statistič-
kih razlika bile su: 0,26 mmol/L (-0,95, 1,47) za TC, i -0,16 mmol/L (-1,29, 0,98) za TG. Podudarnost za klasifi kaciju ispitanika prema smjernicama 
Nacionalnog programa za edukaciju o kolesterolu (engl. National Cholesterol Education Program, NCEP) bila je statistički značajna (P < 0,001) sa 
značajnom podudarnošću za TC (κw = 0,67) te umjerenom za TG (κw=0,50).
Zaključak: Ponovljivost iz dana u dan na uređaju Accutrend® Plus za TC i TG nije optimalna i nedostaje joj točnosti u usporedbi s referentnom 
laboratorijskom metodom. Podudarnost između te dvije metode za klasifi kaciju ispitanika prema smjernicama NCEP je neodgovarajuća. Uređaj 
Accutrend® Plus se ne bi trebao primjenjivati kao potpuna zamjena standardnih laboratorijskih metoda u dijagnostici hiperlipidemije.
Ključne riječi: ponovljivost rezultata; kolesterol; trigliceridi
